Literature DB >> 2965021

Stimulation with dendritic cells decreases or obviates the CD4+ helper cell requirement in cytotoxic T lymphocyte responses.

C J Boog1, J Boes, C J Melief.   

Abstract

We investigated the need for CD4+ helper T (Th) cells in the induction of murine cytotoxic T lymphocyte (Tc) responses across minor or major histocompatibility (MHC) antigenic differences with either normal spleen cells (NSC) or purified dendritic cells (DC) as antigen-presenting cells (APC). Generation of a secondary in vitro class II MHC-specific Tc response was totally CD4+ Th cell-dependent with both types of APC. Likewise, male antigen (H-Y)-primed class II mutant bm12 T cells, which do not respond to H-Y presented on NSC, do respond to H-Y presented on DC in a completely CD4+ Th cell-dependent fashion. All other Tc responses, including primary anti-class I MHC, primary anti-class I + II MHC plus anti-minor H, and secondary C57BL/6 (B6) anti-H-Y, although not completely CD4+ Th cell dependent, were greatly augmented in the presence of CD4+ Th cells, but only with NSC as APC. In contrast, with DC as APC these responses were entirely or largely CD4+ Th cell independent. Similarly, H-Y primed class I MHC mutant bm14 T cells, which do not respond to H-Y presented on NSC, do respond to H-Y presented on DC in a completely CD4+ Th cell-independent fashion. The combined results indicate that DC can directly present class I MHC alloantigen or class I MHC plus nominal antigen (e.g. minor H) to CD8+ cells and generate a Tc response by these cells without the requirement for CD4+ Th cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965021     DOI: 10.1002/eji.1830180206

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells.

Authors:  J W Young; R M Steinman
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

2.  Major histocompatibility complex class II-regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas.

Authors:  W L Vasmel; M Zijlstra; T Radaszkiewicz; C J Leupers; R E de Goede; C J Melief
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

3.  Activity of CD4+ T-cell clones of type 1 and type 2 in generation of influenza virus-specific cytotoxic responses in vitro.

Authors:  G Palladino; P A Scherle; W Gerhard
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

4.  Enhanced tumor susceptibility of immunocompetent mice infected with lymphocytic choriomeningitis virus.

Authors:  M Kohler; B Rüttner; S Cooper; H Hengartner; R M Zinkernagel
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  During HIV-1 infection most blood dendritic cells are not productively infected and can induce allogeneic CD4+ T cells clonal expansion.

Authors:  P U Cameron; U Forsum; H Teppler; A Granelli-Piperno; R M Steinman
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

6.  Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.

Authors:  J W Young; K Inaba
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

7.  Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy.

Authors:  S Valitutti; S Müller; M Dessing; A Lanzavecchia
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

8.  Mechanisms of mouse spleen dendritic cell function in the generation of influenza-specific, cytolytic T lymphocytes.

Authors:  R Nonacs; C Humborg; J P Tam; R M Steinman
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

9.  N-linked glycan modification on antigen-presenting cells restores an allospecific cytotoxic T cell response.

Authors:  J J Neefjes; M L De Bruijn; C J Boog; J D Nieland; J Boes; C J Melief; H L Ploegh
Journal:  J Exp Med       Date:  1990-02-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.